噬菌體市場：現狀分析與預測（2022-2028）

噬菌體市場預計將以 4.5% 的複合年增長率增長。 這是由於全世界患者中抗生素耐藥性日益普遍。 例如，根據疾病控制與預防中心 2021 年 12 月的一份報告，美國各地每年發生超過 280 萬例抗生素感染。 此外，隨著細菌對抗生素的抵抗力增強，對替代治療的需求也隨之增加。 噬菌體可能提供一種解決方案，因為它們可以專門針對並殺死細菌，而不傷害人類或其他生物體。 此外，噬菌體可以針對特定的細菌菌株進行定制，使其比傳統抗生素更有效。 因此，上述因素預計將推動市場增長。

根據產品類型，市場分為益生元和治療前藥物。 其中，益生元領域預計在預測期內將以較大的複合年增長率增長。 益生元可以幫助促進噬菌體生長，減少腸道中有害細菌的數量，並改善您的整體健康。 因此，益生元行業預計將受益於噬菌體市場的增長。 因此，上述因素預計將在預測期內推動市場增長。

根據應用類型，市場分為胃腸道、呼吸道感染、尿路感染等。 其中，呼吸道感染領域預計在預測期內將以較大的複合年增長率增長。 這是由於肺炎球菌引起的肺炎球菌疾病的患病率不斷增加。 例如，根據美國疾病控制與預防中心 2019 年的一份報告，美國每年發生超過 3000 萬例肺炎球菌感染，其中超過 30% 的感染中，該細菌與一種或多種臨床症狀有關。對相關抗生素有耐藥性。 這一因素正在推動市場對噬菌體的需求。

根據給藥途徑，市場分為口服途徑、局部途徑和腸胃外途徑。 其中，口服給藥途徑預計在預測期內將以顯著的複合年增長率增長。 口服給藥途徑因其較高的患者依從性和成本效益而被優選為最方便的給藥途徑。 此外，口服途徑給藥的藥物在設計和製造過程中具有更大的靈活性，並且比其他給藥途徑具有更少的無菌限制。 因此，上述因素正在推動市場增長。

預計亞太地區在預測期內將以顯著的複合年增長率增長。 這是由於該地區醫療保健支出增加。 例如，2021財年支付給醫療機構的醫療保健支出創下歷史新高，達到316萬億美元，比上年增加14萬億美元（4.6%）。 這正在推動該地區的市場增長。

目錄

第一章市場介紹

• 市場定義
• 主要目的
• 利益相關者
• 限制

第二章研究方法或假設

• 調查過程
• 調查方法
• 受訪者簡介

第三章市場總結

第 4 章執行摘要

第五章新型冠狀病毒感染（COVID-19）對全球噬菌體市場的影響

第 6 章全球噬菌體市場收入，2020-2028

第 7 章按產品類型劃分的市場洞察

第 8 章按應用劃分的市場洞察

• 胃腸道
• 呼吸道感染的治療
• 尿路感染
• 其他

第 9 章最終用戶的市場洞察

• 口服途徑
• 本地路線
• 腸胃外途徑

第 10 章按地區劃分的市場洞察

• 北美市場
  • 美國
  • 加拿大
  • 其他北美地區
• 歐洲市場
  • 英國
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 其他歐洲地區
• 亞太市場
  • 中國
  • 日本
  • 印度
  • 韓國
  • 亞太地區的其他國家/地區
• 世界其他地區的市場

第 11 章噬菌體市場動態

• 市場驅動因素
• 市場挑戰
• 影響分析

第12章噬菌體市場機會

第13章噬菌體市場趨勢

第14章需求側和供給側分析

• 需求方分析
• 供給側分析

第 15 章戰略洞察

第16章競爭場景

• 競爭狀況
  • 波特五力分析

第17章公司簡介

• Armata Pharmaceuticals, Inc.
• Life Extension.
• Arthur Andrew Medical.
• Biochimpharm
• Micreos
• biostation.
• Probiotic America, LLC.
• Eliava BioPreparations
• Locus Biosciences, Inc.
• BiomX.

第18章 免責事項

Bacteriophages also known as phage viruses are a group of viruses, that infect and replicate inside bacteria. They are the most abundant biological entities on Earth and play an important role in regulating bacterial populations in various environments. Phages have been used as a therapeutic agent for treating bacterial infections, and they also have potential applications in biotechnology and biodefense.

The bacteriophage market is anticipated to grow with a CAGR of 4.5%. This is attributed to the increase in the prevalence of developing antibiotic resistance amongst patients globally. For instance, according to the Centre for disease control and Prevention's December 2021 report, around the United States, more than 2.8 million anti-microbial infections occur each year. Additionally, as bacteria become increasingly resistant to antibiotics, there is a growing need for alternative treatments. Bacteriophages may offer a solution as they can specifically target and kill bacteria without harming humans or other organisms. Further, bacteriophages can be tailored to specific bacterial strains, which may make them more effective than traditional antibiotics. Thus, the above-mentioned elements are anticipated to boost market growth.

Based on product type, the market is bifurcated into pre-biotic and pre-therapeutics. Amongst this, the pre-biotic segment is anticipated to grow with a significant CAGR in the forecasted period. Pre-biotics can help to promote the growth of bacteriophages, which can help to reduce the number of harmful bacteria in the gut and improve overall health. Therefore, the pre-biotic segment is expected to benefit from the growth of the bacteriophage market. Thus, this above-mentioned factor is anticipated to fuel the market growth in the forecasted period.

Based on the application type, the market is segmented into the gastrointestinal tract, respiratory tract infection, urinary tract infections and others. Amongst this, the respiratory tract infection segment is anticipated to grow with a significant CAGR in the forecasting period. This is attributed to the rising incidence of pneumococcal disease, caused by the bacteria streptococcus pneumonia. For instance, according to the Centre for disease control and Prevention 2019 report, more than 30 million pneumococcal infections occur each year in the United States, amongst this in more than 30% of infections, the bacteria are resistant to one or more clinically relevant antibiotics. This element is driving the market demand for bacteriophage.

Based on the route of administration, the market is segmented into oral, topical and parenteral routes. Amongst these, the oral route of administration is anticipated to grow with a significant CAGR during the forecasting period. oral route of drug administration is preferred and is the most convenient route of drug administration due to its high patient compliance and cost-effectiveness. Additionally, the oral route drugs are flexible in design and production process and have fewer sterility constraints contrary to other routes of administration. Thus, these above-mentioned factors are fueling the growth of the market.

For a better understanding of the market adoption of the Behavior Health industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (UK, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Rest of World. Asia-pacific is anticipated to grow with a significant CAGR during the forecasted period. This is attributed to the increase in healthcare expenditure in this region. For instance, healthcare expenditures paid to medical institutions in fiscal 2021 reached a record USD 316 trillion, an increase of 14 trillion, or 4.6%, compared to the previous year. This is propelling the market growth in this region.

Some of the major players operating in the market include: Armata Pharmaceuticals, Inc., Life Extension., Arthur Andrew Medical., Biochimpharm, Micreos, biostation., Probiotic America, LLC., Eliava BioPreparations, Locus Biosciences, Inc., BiomX.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Bacteriophage Market
• 2.2. Research Methodology of the Bacteriophage Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL BACTERIOPHAGE MARKET COVID-19 IMPACT

6 GLOBAL BACTERIOPHAGE MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY PRODUCT TYPE

• 7.1. Phage Pro-biotic
• 7.2. Phage Therapeutics

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Gastrointestinal tract
• 8.2. Respiratory Infection Treatment
• 8.3. Urinary Tract Infection
• 8.4. Others

9 MARKET INSIGHTS BY END-USERS

• 9.1. Oral
• 9.2. Topical
• 9.3. Parenteral

10 MARKET INSIGHTS BY REGION

• 10.1 North America Market
  • 10.1.1 U.S.
  • 10.1.2 Canada
  • 10.1.3 Rest of North America
• 10.2 Europe Market
  • 10.2.1 UK
  • 10.2.2 Germany
  • 10.2.3 France
  • 10.2.4 Italy
  • 10.2.5 Spain
  • 10.2.6 Rest of Europe
• 10.3 Asia-Pacific Market
  • 10.3.1 China
  • 10.3.2. Japan
  • 10.3.3 India
  • 10.3.4 South Korea
  • 10.3.5 Rest of APAC
• 10.4 Rest of the World Market

11 BACTERIOPHAGE MARKET DYNAMICS

• 11.1 Market Drivers
• 11.2 Market Challenges
• 11.3 Impact Analysis

12 BACTERIOPHAGE MARKET OPPORTUNITIES

13 BACTERIOPHAGE MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1 Demand Side Analysis
• 14.2 Supply Side Analysis

15 STRATEGIC INSIGHTS

16 COMPETITIVE SCENARIO

• 16.1 Competitive Landscape
  • 16.1.1 Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1 Armata Pharmaceuticals, Inc.
• 17.2. Life Extension.
• 17.3 Arthur Andrew Medical.
• 17.4. Biochimpharm
• 17.5. Micreos
• 17.6. biostation.
• 17.7. Probiotic America, LLC.
• 17.8. Eliava BioPreparations
• 17.9. Locus Biosciences, Inc.
• 17.10. BiomX.

18 DISCLAIMER